Risk Management in the Pharmaceutical Product Development Process: White Paper Prepared by PhRMA Drug Product Technology Group

Choice experiment to assess consumer attributes for a pharmaceutical product

Purpose

This study aims to identify the appropriate combination of attributes that must be present to deliver value in a new product for a pharmaceutical enterprise.

Design/methodology/approach

The application object was the Metronidazole analytical standard, using choice experiments to product attributes and price.

Findings

The practical results indicate that consumer value anticipation allows entry into the market with higher competitiveness.

Originality/value

Conceptually, it uses a value delivery approach, generally applied to large companies, in a case aimed at enterprises. In practice, for the enterprise studied, the value anticipation by the consumer allows entry into the market with higher competitiveness.

Quality by Design in Clinical Trials: A Collaborative Pilot With FDA

The quality of a clinical trial can be assessed by whether the trial meets the needs of its various customers, as well as by its freedom from critical deficiencies or errors. In order to ensure the quality of a clinical trial, it is therefore important to conduct quality planning in parallel with the process to design and prior to the conduct of the trial. Quality planning consists of prospectively establishing quality goals and developing the products and processes required to deliver a quality trial. This article describes the quality planning process conducted by a pharmaceutical sponsor for a clinical trial and the pilot review of the resulting integrated quality management plan by the FDA. This pilot demonstrates the usefulness of this process to enable alignment between sponsors and regulators concerning quality in clinical trials.